RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT: NCT04796350 · RECRUITING
Brief Summary
A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.
Frequently Asked Questions
What is RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures?
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures is a clinical trial registered under NCT04796350. Current status: RECRUITING.
What is the status of NCT04796350?
The current status of NCT04796350 (RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures) is: RECRUITING.
When did RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures start?
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures started on 2021-04-24.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.